- In October 2023, Enterome revealed updated results from the Phase 1/2 SPENCER trial, assessing EO2401 combined with nivolumab for the treatment of adrenocortical carcinoma (ACC) and metastatic pheochromocytoma/paraganglioma (MPP), two types of adrenal tumors. The trial aims to evaluate the safety and efficacy of this combination therapy. The updated data highlights the potential of EO2401 as a promising treatment option for these challenging, rare cancers.
- In February 2021, Glenmark Pharmaceuticals, a global research-driven company, introduced SUTIB, the generic version of sunitinib oral capsules, in India. This medication is designed to treat kidney cancer and neuroendocrine tumors, offering a more affordable treatment option for patients. The launch reflects Glenmark’s commitment to improving access to essential cancer therapies in emerging markets such as India.
Frequently Asked Questions
The market is segmented based on Segmentation, By Treatment Type (Sympathetic and Parasympathetic Paragangliomas), Site of Origin (Carotid, Cervical, Vagal Paragangliomas, and Others), Therapy Type (Radiation Therapy, Chemotherapy, Peptide Receptor Radionuclide Therapy (PRRT), and Others), Drugs (Iobenguane I 131, Cyclophosphamide, Vincristine, Dacarbazine and Others), Route of Administration (Oral and Injectable), End- Users (Hospitals, Homecare, Specialty Clinics and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Others) – Industry Trends and Forecast to 2032
.
The Global Paraganglioma Treatment Market size was valued at USD 3.41 USD Billion in 2024.
The Global Paraganglioma Treatment Market is projected to grow at a CAGR of 9.15% during the forecast period of 2025 to 2032.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America..
